We would like to share with you another story highlighting the impact of treatment with anti-GD-2, a trifunctional antibody, one of the latest members of the trifunctional Ab platform.
One of our patients (male, 58 yrs old) was diagnosed with melanoma and metastases to the liver, bone, spleen, lung and peritoneum. He was previously treated with chemotherapy, sorafenib, hyperthermia and dendritic cell vaccine. At the clinic, he received Anti-GD-2 treatment for 6 weeks, side effects were mild and well controlled. 10 weeks after, a PET scan was performed and already showed remarkable reduction of metastases, see images below.
Anti-GD-2 treatment can be applied in many different solid tumors and can induce a therapeutic vaccination (see diagram).